Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:33 15/07/2024 BST			5-day change	1st Jan Change
99.1 ^CHF	-0.96%		+1.93%	+16.77%

07-15	Brace for a flurry of speeches from Fed officials
07-15	European companies cut jobs as economy sputters	RE

NOVARTIS AG : Deutsche Bank reiterates its Buy rating

July 10, 2024 at 11:50 am

In a research note published by Emmanuel Papadakis, Deutsche Bank advises its customers to buy the stock. The target price is unchanged at CHF 110.

Latest news about Novartis AG

Brace for a flurry of speeches from Fed officials	07-15
European companies cut jobs as economy sputters	07-15	RE
MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger	07-15	MT
S&P 500 Rises Week-to-Week, Closes Near Highs Despite Mixed Inflation Data, Bank Earnings	07-12	MT
Novartis Seeks Squeeze Out Approval at MorphoSys AGM	07-12	MT
Global markets live: KKR, Apple, Tesla, Oracle, McDonald's...	07-12
Novartis to Close Technical Research Facility in San Diego, California; 100 Jobs Affected	07-11	MT
Novartis to Close Research Facility in San Diego, California; 100 Jobs Affected	07-11	MT
Markets Powered by Alternating Current	07-10
NOVARTIS AG : Deutsche Bank reiterates its Buy rating	07-10	ZD
SIX to Cap SLI Index Weight of Nestle, Novartis Roche, UBS	07-10	MT
European companies cut jobs as economy sputters	07-09	RE
Lexicon Pharmaceuticals Names Mike Exton CEO, Jeff Wade Operating Chief	07-08	MT
Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code	07-05	MT
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches	07-05	MT
NOVARTIS AG : Berenberg sticks Neutral	07-03	ZD
Carisma Therapeutics Notifies Novartis Pharmaceuticals of Terminated Manufacturing, Supply Agreement	07-02	DJ
NOVARTIS AG : Receives a Buy rating from Jefferies	07-02	ZD
NOVARTIS AG : Deutsche Bank reiterates its Buy rating	07-02	ZD
Fitch Affirms Novartis Ratings on Leading Position in Innovative Pharmaceutical Sector	07-02	MT
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments	07-01	MT
New semester, new state of mind	07-01
NOVARTIS AG : Gets a Buy rating from Goldman Sachs	07-01	ZD
Foreign banks target Switzerland after UBS takeover of Credit Suisse	06-24	RE
NOVARTIS AG : Barclays reaffirms its Sell rating	06-24	ZD

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

18/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 06:24 pm

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 12:18 pm

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 03:32 pm

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

110.8 USD

Average target price

112.7 USD

Spread / Average Target

+1.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+16.77%	226B
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+39.42%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+14.19%	244B
ROCHE HOLDING AG	+5.81%	234B
AMGEN INC.	+14.63%	177B
PFIZER, INC.	+1.08%	165B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : Deutsche Bank reiterates its Buy rating

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals